Journal article · 2024 · Open access

Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology

Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, Veerle van Lieshout, An Snellinx, Emanuela Pasciuto, Leen Wolfs, Katleen Craessaerts, Katrien Horré, Tom Jaspers, Mark W. E. J. Fiers, Maarten Dewilde and 1 more

Alzheimer s & Dementia, 20(S1), e087213 · Published 1 December 2024 · DOI 10.1002/alz.087213

Open PDFView at the publisherCite this paper

In brief

“Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology” is a 2024 journal article by Giulia Albertini and 12 co-authors, published in Alzheimer s & Dementia. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Alzheimer s & Dementia.

Citations
0
Authors
13

Abstract

BACKGROUND: While social and medical debate about the efficacy and safety of anti-Aβ immunotherapy is ongoing, one thing that emerged is that we have little understanding of the working mechanisms of these antibodies and this lack of knowledge complicates the interpretation of the clinical results. Here, we aimed to establish if microglia are required for the efficacy of Lecanemab, one of the most promising FDA-approved disease-modifying therapy for AD (Van Dyck et al. N Engl J Med 2023). METHOD: mice (Rojo et al. Nat Commun 2019) to generate mice that show key features of Aβ pathology but genetically lack mouse microglia. We then assessed the effect of Lecanemab treatment on Aβ load and neuritic dystrophy. RESULT: We demonstrate that Lecanemab lacks efficacy in the absence of microglia. On the other hand, when we xenotransplant human microglia into the brain of these mice (as described in Mancuso et al. Nat Neurosci 2019), we show that Lecanemab treatment significantly ameliorates both Aβ load and neuritic dystrophy. Furthermore, by employing scRNAseq on sorted human microglia, we demonstrate that Lecanemab treatment affects the transcriptome of the microglia by inducing a number of genes related phagocytosis, interferon response and immune activation. Functionally, we also established that Lecanemab-treated human microglia ingest more amyloid-β in vivo. CONCLUSION: Overall, we provide the first evidence that microglia are crucial for the efficacy of anti-Aβ immunotherapy and provide real insight into the working mechanisms of this first disease-modifying therapy for AD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Albertini, G., Zielonka, M., Cuypers, M., van Lieshout, V., Snellinx, A., Pasciuto, E., Wolfs, L., Craessaerts, K., Horré, K., Jaspers, T., Fiers, M. W. E. J., Dewilde, M., & De Strooper, B. (2024). Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology. Alzheimer s & Dementia, 20(S1), e087213. https://doi.org/10.1002/alz.087213

MLA 9

Albertini, Giulia, et al. “Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology.” Alzheimer s & Dementia, vol. 20, no. S1, 2024, p. e087213. https://doi.org/10.1002/alz.087213.

Chicago

Albertini, Giulia, Magdalena Zielonka, Marie‐Lynn Cuypers, Veerle van Lieshout, An Snellinx, Emanuela Pasciuto, Leen Wolfs, et al. 2024. “Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology.” Alzheimer s & Dementia 20 (S1): e087213. https://doi.org/10.1002/alz.087213.

Harvard

Albertini, G. et al. (2024) ‘Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology’, Alzheimer s & Dementia, 20(S1), p. e087213. doi:10.1002/alz.087213.

IEEE

G. Albertini et al., “Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology,” Alzheimer s & Dementia, vol. 20, no. S1, p. e087213, 2024, doi: 10.1002/alz.087213.

BibTeX

@article{albertini2024using,
  title     = {{Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology}},
  author    = {Albertini, Giulia and Zielonka, Magdalena and Cuypers, Marie‐Lynn and van Lieshout, Veerle and Snellinx, An and Pasciuto, Emanuela and Wolfs, Leen and Craessaerts, Katleen and Horré, Katrien and Jaspers, Tom and Fiers, Mark W. E. J. and Dewilde, Maarten and De Strooper, Bart},
  journal   = {Alzheimer s \& Dementia},
  year      = {2024},
  volume    = {20},
  number    = {S1},
  pages     = {e087213},
  doi       = {10.1002/alz.087213},
  url       = {https://doi.org/10.1002/alz.087213}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • lecanemab

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Albertini, G., Zielonka, M., Cuypers, M., van Lieshout, V., Snellinx, A., Pasciuto, E., Wolfs, L., Craessaerts, K., Horré, K., Jaspers, T., Fiers, M. W. E. J., Dewilde, M., & De Strooper, B. (2024). Using anti‐Aβ antibodies to modulate the multi‐pronged human microglia response to Aβ pathology. Alzheimer s & Dementia, 20(S1), e087213. https://doi.org/10.1002/alz.087213

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Alzheimer s & Dementia: sign in and open the PDF from this page.

Who wrote this paper?

Giulia Albertini, Magdalena Zielonka, Marie‐Lynn Cuypers, Veerle van Lieshout, An Snellinx, Emanuela Pasciuto, Leen Wolfs, Katleen Craessaerts, Katrien Horré, Tom Jaspers, Mark W. E. J. Fiers, Maarten Dewilde and 1 more.

What is the DOI of this paper?

10.1002/alz.087213, permanently at https://doi.org/10.1002/alz.087213. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.